BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, May 13, 2024
See today's BioWorld
Home
» GSK Takes on 3 More Prosensa Exon-Skipping DMD Drugs
To read the full story,
subscribe
or
sign in
.
GSK Takes on 3 More Prosensa Exon-Skipping DMD Drugs
Sep. 14, 2011
By
Cormac Sheridan
No Comments
Prosensa Therapeutics BV and GlaxoSmithKline plc are moving forward with three additional exon-skipping antisense oligonucleotides as part of their alliance in Duchenne's muscular dystrophy (DMD).
BioWorld